Naso-orbito-ethmoidal fracture main cause of traumatic NLDO

Article

Naso-orbito-ethmoidal fracture has been discovered as the main cause of traumatic nasolacrimal duct obstruction (NLDO), according to a paper in the European Journal of Ophthalmology.

Naso-orbito-ethmoidal fracture has been discovered as the main cause of traumatic nasolacrimal duct obstruction (NLDO), according to a paper in the European Journal of Ophthalmology.

Dr Bipasha Mukherjee et al., Department of Orbit, Oculoplasty, Reconstructive, and Aesthetic Surgery, Medical Research Foundation, Sankara Nethralaya, Chennai, India, reviewed 28 patients in the study. They retrospectively analysed data of the nature and pattern of injury, associated damage, clinical features, investigations, management, outcome and follow-up.

The most common cause of traumatic NLDO was high-velocity blunt injury encountered in road traffic accidents in 70% of patients, with the most common pattern of injury being naso-orbital-ethmoidal fractures in 64% of patients. Traumatic telecanthus was most commonly linked to periocular injury.

Of the the patients investigated, 75% were analysed with computed tomography-dacryocystography. External dacryocystorhinostomy was used to treat26 patients with or without silicon intubation and 2 patients underwent dacryocystorhinostomy. General and local anaesthesia was given to 68% and 32% of patients, respectively.

There was a successful outcome recorded in 96% of eyes operated with external dacryocystorhinostomy with or without silicone intubation. Telecanthus is an important presenting feature in the patients, with naso-orbito-ethmoidal fracture as the main cause of traumatic NLDO.

For the abstract please visit this page.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.